Clinical trials: Squamous Cell Carcinoma (SCC)
Lung Cancer Adenocarcinoma, Lung Cancer Squamous Cell
Glypican-1 Expression in Epithelioid Mesothelioma, Adenocarcinoma and SCC of the Lung
Lung carcinoma is the second most common cancer and a leading cause of cancer-related mortality worldwide. In Egypt, lung carcinoma ranks the 5th among all cancer cases.
- Conditions
- Lung Cancer Adenocarcinoma, Lung Cancer Squamous Cell, Mesothelioma; Lung
- Trial name
- NCT05228795
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Sohag University
Actinic Keratosis, Squamous Cell Carcinoma
A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
One of the main reasons for treating actinic keratoses (AK) is the wish to lower the risk of progression of AK to squamous cell carcinoma (SCC).
- Trial name
- NCT03115476
- Testing
- ingenol disoxate gel 0.018%, ingenol disoxate gel 0.037%, Vehicle gel
- Where
- 59 sites in United States, Canada and 4 more
- Volunteers
- 563 people
- Sponsor
- LEO Pharma
Oral Cavity Squamous Cell Carcinoma, Saliva Altered
Salivary Ap4A, SCCA, TROP2 in Oral Cancer Patients
According to the World Health Organization, oral cancer (OC) is the eighth most common cancer in the world with a five year survival rate of 50%.
- Conditions
- Oral Cavity Squamous Cell Carcinoma, Saliva Altered, Precancerous Lesions
- Trial name
- OCSALTM (NCT03529604)
- Testing
- Saliva sampling, ELISA, HPLC
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Zagreb
Oral Cancer
Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell Line
Squamous cell carcinoma (SCC) is the most common oral cavity carcinoma. Conventional therapeutic modalities for oral malignancy include surgery, radiotherapy and chemotherapy alone or in combinations.The major obstacle of using…
- Trial name
- NCT05456022
- Testing
- Quercetin 3,3',4',5,6-Pentahydroxyflavone, 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one, Quercetin-encapsulated PLGA-PEG nanoparticles (Nano-QUT), Doxorubicin chemotherapeutic drug as a positive control
- Where
- Egypt
- Volunteers
- 1,000,000 people
- Sponsor
- Cairo University
Carcinoma, Squamous Cell
Randomized Multicenter Study of 5 vs 6 Weekly Fraction of RT in the Treatment of SCC of the Head and Neck
Randomized multicenter study of 5 vs 6 weekly fraction of RT in the treatment of SCC of the head and neck
- Trial name
- NCT00534950
- Testing
- 5 vs 6 weekly fraction of RT
- Where
- Saudi Arabia
- Volunteers
- 200 people
- Sponsor
- King Faisal Specialist Hospital & Research Center